Dr. Reddy's announces the re-launch of over-the-counter Famotidine Tablets USP, 10 mg and 20 mg, store-brand equivalent of Pepcid AC® in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the relaunch of over-the-counter (OTC) Famotidine Tablets USP, 10 mg and 20 mg, the store-brand equivalents of Original Strength and Maximum Strength Pepcid AC®, in the U.S. market, as approved by the U.S. Food and Drug Administration (USFDA).

Dr. Reddy's OTC Famotidine Tablets USP, 10 mg and 20 mg, are acid reducers that prevent and relieve heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain food and beverages.

"We are pleased to continue to expand our OTC Antacid portfolio for our customers and consumers," says Marc Kikuchi, CEO, North America Generics, Dr. Reddy's Laboratories. "This launch will help us fulfil an important therapy gap created in Antacids market due to Ranitidine withdrawal."

The Pepcid AC® brand and generic had U.S. sales of approximately $211 million for the most recent twelve months ending in August 2020 according to IRi*.

Dr. Reddy's OTC Famotidine Tablets USP, 10 mg and 20 mg, are available in multiple pack sizes to allow consumers a variety of purchasing options.

Pepcid AC® is a registered trademark of Johnson & Johnson.

Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.5051.45 as compared to the previous close of Rs. 5082.35. The total number of shares traded during the day was 79517 in over 7573 trades.

The stock hit an intraday high of Rs. 5213.5 and intraday low of 5040.4. The net turnover during the day was Rs. 404368456.

Source : Equity Bulls

Keywords